NEAL ANTHONY SCOTT, M.D., Ph.D.
Curriculum Vitae
PROFESSIONAL ADDRESS
515 South Drive, Suite 23
Mountain View, CA 94040
Telephone: (650) 961-7021
CURRENT TITLE AND AFFILIATION
Cardiologist, Heart and Vascular Associates, Mountain View, CA
Consultant
EDUCATION
M.D., Harvard Medical School, Boston, MA
Ph.D., Massachusetts Institute of Technology, Cambridge, MA (Neural and Endocrine Regulation)
B.S., Stanford University, Stanford, CA (Chemistry)
POSTGRADUATE TRAINING
Intern, Internal Medicine, Univ. of California, San Diego
Resident, Internal Medicine, Univ. of California, San Diego
Fellow in Cardiology, Stanford University, Stanford, CA
Postdoctoral Research Fellow, UC San Diego
Fellow in Coronary Interventions, Emory University Medical Center, Atlanta, GA
ACADEMIC APPOINTMENTS
Primary Appointments:
1998-2001 Associate Professor, Emory University School of Medicine, Atlanta, GA
1990-1998 Assistant Professor, Emory University School of Medicine, Atlanta, GA
Secondary Appointments:
1986 – 1989 Clinical Instructor, Stanford University, Stanford, CA
1990 - 2001 Collaborative Scientist, Yerkes Regional Primate Center, Atlanta, GA
CLINICAL APPOINTMENTS
1986 – 1989 Emergency Dept. and Life Flight Attending, Stanford University
1987 – 1989 Life Flight Attending, UC San Diego
1990 – 2001 Cardiology Attending, Emory University Hospital, Atlanta, GA
1990 – 2001 Cardiology and Internal Medicine Attending, Grady Memorial Hospital, Atlanta, GA
1990 – 1994 Cardiology Attending, Atlanta Veterans Administration Hospital, Atlanta, GA
1990 – 1994 Member, The Emory Clinic, Atlanta, GA
1994 - 2001 Senior Member, The Emory Clinic, Atlanta, GA
2002 - Cardiologist, El Camino Hospital, Mountain View, CA
2005 - Cardiologist, O’Connor Hospital, San Jose, CA
2006 - Cardiologist, Palo Alto Veterans Administration Hospital, Palo Alto, CA
LICENSURES
1989 - 2003 Licensed Physician, State of Georgia
1984 - 1990 Licensed Physician, State of California
2002 - Licensed Physician, State of California
BOARD CERTIFICATIONS
Interventional Cardiology, American Board of Internal Medicine
Cardiovascular Diseases, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
INDUSTRY EXPERIENCE
Dr. Scott was a founder of two medical device companies. One was purchased by Medtronic Inc. The intellectual property for the second was purchased by Boston Scientific, Inc. Dr. Scott is a consultant to medical device companies.
MANUSCRIPT REVIEWER
Ad Hoc Reviewer:
Circulation
Journal of the American College of Cardiology
American Journal of Cardiology
Catheterization and Cardiovascular Interventions
Coronary Artery Disease
American Heart Journal
American Journal of Medical Sciences
AWARDS AND HONORS
1992-1994 Robert Wood Johnson Fellowship for Minority Faculty Development
1987-1989 Robert Wood Johnson Fellowship for Minority Faculty Development
1982 Kaiser Merit Fellowship (Harvard Medical School)
1979-1981 Whitaker Health Sciences Fellowship (Massachusetts Institute of Technology)
Sandoz Foundation Fellowship (Massachusetts Institute of Technology)
SOCIETY MEMBERSHIPS
1993 - Fellow, American College of Cardiology
1991 - Member, American Heart Association
PATENTS
ISSUED
Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S. Patent Number: 5,026,685. Issued: June 25, 1991.
Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S. Patent Number: 5,328,899. Issued: Jul. 12, 1994
Scott NA, Hanson SR, King SB III, Harker LA. Stent sheath for local drug delivery. U.S. Patent Number 5,383,928. Issued: January 24, 1995.
Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery and methods for using the same. U.S. Patent Number 5,523,092. Issued: June 4, 1996.
Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery and methods for using the same. U.S. Patent Number 5,709,874. Issued: January 20, 1998.
Hanson SR, Scott NA, Markou C, King SB III. Device and method for non-occlusive localized drug delivery. U.S. Patent Number 5,985,307. Issued: November 16, 1999.
Waksman R, King SB, Scott NA. Endovascular support device and method of use. U. S. Patent Number 6,355,055. Issued: March 12, 2002.
Hampikian JM, Scott NA. Radioactive coating solutions, methods and substrates. US Patent Number 6,475,644 B1. Issued: November 5, 2002
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,292,885. Issued: November 7, 2007.
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,488,313. Issued: February 10, 2009
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,488,314. Issued: February 10, 2009
Scott NA, Segal J, Shih LB, Harris S, Burkoth T. Polymer coated device for electrically mediated drug delivery. US Patent Number 7,517,342. Issued: April 14, 2009.
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,519,418. Issued: April 14, 2009.
PATENTS PENDING (published):
Scott NA, King SB III. Catheter and method for ostial stent placement (European Patent Application).
Scott NA, Hampikian JM. Bachytherapy device and method of use. US Patent Application # 20030092957.
Segal J, Hampikian JM, Scott NA. Device and method for dilating and irradiating a vascular segment or body passageway. US Patent Application # 20020077520.
Scott NA, Segal J. Charged liposomes or micelles with encapsulated medical compounds. US Patent Application # 20040034336.
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Application # 20050038409.
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Application # 20040267356.
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment US Patent Application # 20040267355.
Scott NA, Segal J, Burkoth T, Harris S. High concentration medicament and polymer coated device for passive diffusional drug delivery. US Patent Application # 2005/0159704.
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Application #2005/0054978.
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Application # 20050043680.
PUBLICATIONS (selected)
Scott NA, DeSilva RA, Lown B, Wurtman RJ. Tyrosine administration decreases vulnerability to ventricular fibrillation in the normal canine heart. Science 211:727-729, 1981.
Reinstein DK, Lehnert H, Scott NA, Wurtman RJ. Tyrosine prevents behavioral and neurochemical correlates of an acute stress in rats. Life Sciences 34:2225-2231, 1984.
Maisel AS, Scott NA, Gilpin E, Ahnve S, LeWinter M, Henning H, Collins D, Ross J. Complex ventricular arrhythmias in Qwave versus non-Q-wave myocardial infarction. Circulation 72:963-970, 1985.
Scott NA, Webb V, Boublik JH, Rivier J, Brown M. The cardiovascular actions of centrally administered Neuropeptide Y. Regulatory Peptides 25: 247-258,1989.
Boublik JH, Scott NA, Brown MR, Rivier J. Structure-activity relationships of D-substituted and N-terminally modified analogs and C- and N- terminal fragments of neuropeptide Y. J Med Chem 32:597-601, 1989.
Maisel AS, Scott NA, Motulsky HJ, Ziegler M, Brown MR. Elevation of Neuropeptide Y in congestive heart failure. Am J Med 86:43-48, 1989.
Boublik JH, Scott NA, Taulane J, Goodman M, Brown M, Rivier J. Neuropeptide Y and Neuropeptide Y 18-36; structural and biological characterization. Intl J Pept Prot Res 33:11-15,1989.
Scott NA, Michel MC, Boublik JH, Rivier JE, Motomura S, Crum RL, Landon M, Brown MR. Distinction of NPY receptors in vitro and in vivo II. Differential effects of NPY and NPY-(18-36). Am J Physiol 259:H174-H180, 1990.
Boublik JH, Spicer MA, Scott NA, Brown MR, Rivier JE. Biologically active Neuropeptide Y analogs. Ann NY Acad Sci 611:27-34,1990.
Allen RA, Boublik J, Hauger RL, Scott N, Rivier J, Brown MR. Neuropeptide Y radioimmunoassay: characterization and application. Clinical and Experimental Pharmacology and Physiology 18: 825-833, 1991.
Feinstein RD, Boublik JH, Kirby D, Spicer MA, Craig AG, Malewicz K, Scott NA, Brown MR, Rivier JE. Structural requirements for Neuropeptide Y18-36 evoked hypotension: a systematic study. J Med Chem 35: 2836-2843, 1992.
Segal J, Kern MJ, Scott NA, King SB 3rd, Doucette JW, Heuser RR, Offili E, Siegel R. Alterations of phasic coronary artery flow velocity in humans during percutaneous coronary angioplasty. J Am Coll Cardiol 20: 276-286, 1992.
Scott NA, King SB 3rd. Coronary stents. Coronary Artery Dis 3:901-907, 1992.
Scott NA, Weintraub WS, Carlin SF, Tao X, Douglas JS Jr, Lembo NJ, King SB 3rd. Recent changes in the management of acute closure during coronary angioplasty. Am J Cardiol 71:1159-1163, 1993.
Vyavahare N, Scott NA, Hanson SR, Kohn J. In vitro and in vivo evaluation of the site specific administration of d-phenylalanyl-l-prolyl-l-arginyl chloromethyl ketone (PPACK) - a powerful thrombin inhibitor. Journal of Controlled Release 27:165-173,1993.
Scott NA, Kelsey SF, Detre K, Cowley MJ, King SB 3rd, and the NHLBI PTCA Registry Investigators. Percutaneous Transluminal Coronary Angioplasty in African-Americans: an analysis of the National Heart, Lung and Blood Institute PTCA Registry. Amer J Cardiol 73:1141-1146, 1994.
Scott NA, Pettigrew RI. Absence of movement of coronary stents after placement in a magnetic resonance imaging field. Amer J Cardiol 73:900-901, 1994.
Nunes GL, Hanson SR, King SB 3rd, Sahatjian RA, Scott NA. Local delivery of an antithrombin with a hydrogel-coated PTCA balloon catheter inhibits platelet-dependent thrombosis. J Amer Coll Cardiol 23: 1578-1583, 1994.
Waksman R, Ghazzal ZMB, Scott NA, Douglas JS Jr, King SB 3rd. Efficacy and safety of using perfusion dilatation catheter as initial balloon in coronary angioplasty. Catheter Cardiovasc Diagnosis 32:319-322, 1994.
Scott NA, Nunes GL, King SB 3rd, Harker LA, Hanson SR. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation 90:1951-1955, 1994.
Robinson KA, Candal FJ, Scott NA, Ades EW. Seeding of vascular grafts with an immortalized human dermal microvascular endothelial cell line. Angiology 46:107-13, 1995.
Waksman R, Douglas JS Jr, Scott NA, Ghazzal ZM. Yee-Peterson J, King SB 3rd. Distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. Amer Heart Journal 129:430-5, 1995.
Scott NA, Thomas CN, Nunes GL, Robinson KA, Rowland SM, Juman I, Harker LA, King SB 3rd, Hanson SR. A comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Amer Heart Journal 129:866-72, 1995.
Scott NA, Candal FJ, Robinson KA, Ades EW. Seeding of intracoronary stents with immortalized human microvascular endothelial cells. Amer Heart Journal 129:860-66, 1995.
Scott NA. Current status and potential applications of drug delivery balloon catheters. J Interventional Cardiology 8:406-419, 1995.
Scott NA, McManamon R, Strobert E, Cipolla G, Tarazona N, Swenson RB. In-vivo diagnosis of coronary artery disease in a gorilla. J Zoo and Wildlife Med 26:139-143, 1995.
Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB 3rd, Scott NA. Local delivery of heparin via a hydrogel-coated PTCA balloon catheter inhibits platelet-dependent thrombosis. Circulation 92:1697-1700, 1995.
Thomas CN, Weintraub WS, Shen Y, Ghazzal ZMB, Douglas JS Jr, King SB 3rd, Scott NA. Bailout coronary stenting in patients with a recent myocardial infarction. Amer J Cardiol 77: 653-655, 1996.
Waksman R, Scott NA, Ghazzal ZMB, Mays R, Frerichs FA, Petersen JY, King SB 3rd. A randomized comparison of flexible versus non-flexible femoral sheaths on patient comfort after angioplasty. Amer Heart Journal 131: 1076-1078, 1996.
Scott NA, Cipolla GD, Ross CE, Dunn B, Martin F, Simonet L, Wilcox JN. Potential role of the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 93: 2178-2187, 1996.
Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. International J Cardiol 54: (Suppl.) S21-S35, 1996.
Thomas CN, Robinson KA, Cipolla GL, King SB 3rd, Scott NA. Local intracoronary delivery of heparin with a microporous balloon catheter. Amer Heart Journal 132: 969-972, 1996.
Wilcox JN, Waksman R, King SB 3rd, Scott NA. The role of the adventitia in the arterial response to angioplasty. International Journal of Radiation Oncology, Biology, Physics 36: 789- 796, 1996.
Jones SA, Leclerc H, Chatzimavroudis GP, Kim YH, Scott NA, Yoganathan AP. The influence of acoustic impedance mismatch on post-stenotic pulsed-doppler ultrasound measurements in a coronary artery model. Ultrasound in Medicine & Biology 22: 623-34, 1996.
Wilcox JN, Cipolla GD, Martin FH, Simonet L, Dunn B, Ross CE, Scott NA.Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann NY Acad Sci 811:437-47, 1997.
De Leon H, Scott NA, Martin F, Simonet L, Bernstein KE, Wilcox JN. Expression of nonmuscle myosin heavy chain-B isoform in the vessel wall of porcine coronary arteries after balloon angioplasty. Circulation Research 80:514-519, 1997.
Waksman R, Rodriguez JC, Robinson KA, Cipolla GD, Crocker IR, Scott NA, King SB 3rd, Wilcox JN. Effect of intravascular irradiation on cell proliferation, apoptosis and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 96:1944-1952, 1997.
Waksman R, Weintraub WS, Ghazzal ZMB, Scott NA, Shen Y, King SB 3rd, Douglas JS Jr. Acute and long-term outcome of narrowed saphenous vein bypass graft. A comparison of treatment with Palmaz-Schatz stent, directional coronary atherectomy and balloon angioplasty. Amer Heart J 134(2 Pt 1):274-81, 1997.
Viel K, Cui J, Thomas CN, Nunes GL, Cipolla G, King SB 3rd, Scott NA. Inhibition of platelet deposition with local delivery of heparin using a double balloon catheter. Thrombosis Research 88:147-157, 1997.
Scott NA. Hyperlipidemia in African-Americans. ABC Digest of Urban Cardiology 4:17-22, 1997.
Scott NA, Wilcox JN. Role of the adventitial vasculature in resteonsis: a new view of an old problem. J Amer Coll Cardiol 32 (7): 2080, 1998.
Levy D, Merz CNB, Cody RJ, Fouad-Tarazi FM, Francis CK, Pfeffer MA, Scott NA, Swan HJC, Taylor MP, Weinberger MH. Hypertension detection, treatment and control. A call to action for cardiovascular specialists. J Amer Coll Cardiol 34:1360-1361, 1999.
Scott NA. The soft x-ray catheter system. Current Interventional Cardiology Reports 1:48-50, 1999
Scott NA, Crocker IR, Yin QQ, Sorescu D, Wilcox JN, Griendling KK.Inhibition of vascular cell growth by x-ray irradiation: comparison with gamma radiation and mechanism of action. Inter J Radiation Oncology, Biology and Physics 50:485-493, 2001.
Garas SM, Huber P, Scott NA. Overview of therapeutics for prevention of restenosis after coronary interventions. Pharmacology and Therapeutics 92 (2-3):165-78, 2001.
Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104: 2228-35, 2001.
Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Advanced Drug Delivery Reviews 3: 358-376, 2006.
